Pharmacyclics LLC focuses on developing novel therapies for the treatment of cancer and immune-mediated diseases in the United States. The company markets IMBRUVICA, a single-agent therapy used for the treatment of patients with chronic lymphocytic leukemia, mantle cell lymphoma and waldenström's macroglobulinemia. It also has several product candidates in clinical development. The company was founded in 1991 and is headquartered in Sunnyvale, California.